Regulatory filing 📈 Stocks 🌍 United States

Rallybio Sets November 20 Merger Close and $13.90 Cash Distribution Date

Rallybio Corporation expects to finalize its merger with Avenzo Therapeutics on November 20, 2026, while confirming a $13.90 per share cash distribution payable starting November 30, 2026.

📅 November 12, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: RLYB ↑ 4/10 (75% confidence).

📊 Affected Assets (1)

RLYB

Bullish 🤖 75%

📅 Short-term 🌍 US · Explicit

The 8-K confirms the Avenzo Therapeutics merger will close after trading on November 20, 2026, Nasdaq has approved the new listing, and the $13.90 per share special cash distribution remains on track for November 30, 2026. This de-risks the previously announced deal timeline and locks in the cash payment mechanics for holders. The main residual risk is that closing conditions could still be unsatisfied, delaying the transaction.

Catalysts

▲ Merger closing expected after the close of trading on November 20, 2026
▲ Special cash distribution of $13.90 per share, payable to holders of record as of November 5, 2026, with payment starting November 30, 2026

Risk Factors

▼ Closing conditions of the Merger Agreement (dated May 31, 2026) must still be satisfied or waived and the deal could be delayed or terminated
▼ The reverse stock split effective November 20, 2026 may not produce a sustained price increase or ensure Nasdaq compliance

🧭 Full analysis of these assets

🎯 Key Takeaways

The merger with Avenzo Therapeutics is slated to close following the close of trading on November 20, 2026.
A $13.90 per share cash distribution will be paid to eligible holders starting November 30, 2026.
Nasdaq has approved the listing of the combined company's common stock.
Due bill procedures apply to trades through November 20, 2026, requiring investors to hold shares through that date to receive the cash distribution.

📝 Executive Summary

Rallybio Corporation confirmed its merger with Avenzo Therapeutics is expected to close after trading on November 20, 2026. The company also finalized details for a $13.90 per share cash distribution, with payments scheduled to commence on November 30, 2026, for eligible holders.

❓ FAQ

When will Rallybio shareholders receive the $13.90 per share cash distribution?

The distribution is deposited with the transfer agent on November 19, 2026 and payments are expected to begin November 30, 2026 to holders of record as of November 5, 2026 who hold through the close of trading on November 20, 2026 due to due bill procedures.

When does the merger with Avenzo Therapeutics close?

The company expects the merger to close following the close of trading on November 20, 2026, subject to satisfaction or waiver of any outstanding closing conditions, with the new listing on Nasdaq already approved.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article